Pharmacokinetics of platinum following the administration of cis-(Glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in dogs

Dae Kee Kim, Hun Taek Kim, Yong Baik Cho, Taek Soo Kim, Key H. Kim, Weon Seon Hong

Research output: Contribution to journalArticlepeer-review

Abstract

The pharmacokinetic study on cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] -platinum(II) (SKI 2034R, NSC D642489) was performed in beagle dogs. A single dose of 2.0 mg/kg of SKI 2034R was given by i.v. bolus to three beagle dogs. Plasma samples were analyzed for platinum by flameless atomic absorption spectrophotometry. Plasma concentrations of total and ultrafiltrable platinum for SKI 2034R declined in a biexponential fashion. The mean area under the concentration-time curve (AUC(0→∞)) determined for ultrafiltrable platinum derived from SKI 2034R, as an active component, was 2.76 ± 0.13 ug·h/ml (mean ± S.D.), with an initial half-life of 0.15 ± 0.09 hour, a terminal half-life of 0.96 ± 0.12 hour, a total clearance of 12.07 ± 0.67 ml/min/kg, and a steady-state volume of distribution of 0.82 ± 0.06 l/kg.

Original languageEnglish
Pages (from-to)3681-3683
Number of pages3
JournalAnticancer Research
Volume17
Issue number5 A
StatePublished - Sep 1997

Keywords

  • New platinum complex (SKI 2034R)
  • Pharmacokinetics

Fingerprint

Dive into the research topics of 'Pharmacokinetics of platinum following the administration of cis-(Glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in dogs'. Together they form a unique fingerprint.

Cite this